查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1522692

HIV治疗剂和注射市场：2024-2034

HIV Drugs and Injectables Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 288 Pages | 商品交期: 最快1-2个工作天内

价格

到 2034 年，全球 HIV 治疗药物和注射剂市场规模预计将以 4.6% 的复合年增长率成长。

该报告调查了全球爱滋病毒治疗药物和注射剂市场，并提供了市场概况、影响市场成长和市场机会的因素分析、市场规模的趋势和预测，以及各个区隔市场、地区和主要国家的详细资讯。竞争格局、主要公司概况等。

目录

第1章 报告概述

第2章 执行摘要

第3章 市场概况

  • 主要发现
  • 市场动态
  • 影响分析
    • 市场驱动力
    • 市场限制因素
    • 市场机会
  • COVID-19 影响分析
  • 供应链分析
  • 监管框架
  • 波特五力分析
  • PEST分析
  • 新兴市场和大趋势

第4章 HIV 治疗药物和注射市场分析：依药物类别

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 合併治疗（包括 InSTI）
  • 核甘和非核甘 RTI
  • 蛋白□抑制剂
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第5章 HIV口服治疗药物市场

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势与预测：按品牌
  • Biktarvy
  • Complera
  • Delstrigo
  • Dovato
  • Genvoya
  • Juluca
  • Odefsey
  • Stribild
  • Symtuza
  • Triumeq
  • Descovy
  • Truvada
  • Edurant
  • Pifeltro
  • Rukobia
  • Prezista
  • Isentress
  • Tivicay

第6章 HIV 长效注射剂市场分析：依药物分类

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • Cabenuva
  • Sunlenca
  • Trogarzo
  • Enfuvirtide (generic)

第7章 HIV 暴露前预防 (PrEP) 注射剂的分析：按药物分类

  • 主要发现
  • 市场规模趋势和预测
  • Apretude
  • Lenacapavir (PrEP)

第8章 HIV 注射剂市场分析：依口服疗法类型

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 品牌
  • 通用的
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第9章 HIV 治疗药物和注射市场分析：按分销管道

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 医院药房
  • 零售药店
  • 网上药店
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第10章 HIV 治疗药物和注射剂市场分析：管道分析

  • 主要发现

第11章 HIV 治疗药物和注射市场分析：按地区

  • 主要发现
  • 市场规模趋势和预测

第12章 北美HIV药物和注射市场分析

第13章 欧洲爱滋病药物和注射市场分析

第14章 亚太地区HIV药物和注射剂市场分析

第15章 拉丁美洲爱滋病药物和注射市场分析

第16章 中东和非洲HIV药物和注射剂市场分析

第17章 公司简介

  • 竞争格局
  • 战略视角
  • ViiV Healthcare (a GSK company)
  • Gilead Sciences, Inc.
  • Merck KGaA
  • AbbVie Inc.
  • J&J Innovative Medicine (formerly Janssen Pharma)
  • Theratechnologies Inc.
  • Teva Pharmaceuticals Inc.
  • Frontier Biotechnologies Inc.
  • Bristol Myers Squibb Inc.

第18章 一般性意见/建议

  • Visiongain 的一般评论
  • 对进入市场的企业的建议
Product Code: PHA1350

The global HIV Drugs & Injectables market is projected to grow at a CAGR of 4.6 % by 2034

The HIV Drugs & Injectables Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Demand for Newer Drugs Poses a Challenge for Generic Manufacturers

The patients undergoing HIV treatment regimens prefer to take newly launched drugs over the previous blockbuster HIV drugs or generic drugs owing to fact that new drugs tend to be safer with fewer side-effects and are less likely to develop early drug resistance due to which very limited generic drug manufacturers are operating in this sector. The three major players of generic HIV drugs market include Aurobindo, Cipla and Mylan. These companies are capable of manufacturing a wide range of generics and can generate profits despite decline in demand, while it becomes difficult for small generic manufacturers. Thus, fast changing drug science and new drug launches make certain drugs obsolete for example in recent years few of the blockbuster drugs such as Crixivan (indinavir), Invirase (saquinavir), Rescriptor (delaviridine), Videx (didanosine) Viracept (nelfinavir), and Zerit (stavudine) have all been removed from the market. Moreover, some of the innovator companies are also signing pay for delay pact with the generic firms to delay the launch of generics in the market and retain their monopolistic status.

Lack of Trained Staff and Infrastructural Facilities

There has been a growing demand for LAI for HIV treatment and PrEP however pressing needs pertaining training, staffing, storage and refrigeration in certain cases have been a major hurdle for implementing LA HIV regimens. Private groups do not staff nurses and might need to hire nurses and storage systems for administration of these injectables. Role of pharmacies and HIV care systems through its existing networks needs to be considered for widescale deployment of LAIs. Post pandemic there has been a rise in administration of wide variety of medication classes by the pharmacy staff. These pharmacies and community-based drugstores can be commissioned to delivery of LAI by pharmacy staff, while policymakers can incentivize these services offered at these places. Moreover, changes in electronic health record systems, restructuring of the clinic visits needs to be spanned out for effective and smooth implementation of LAI injectables for HIV.

What Questions Should You Ask before Buying a Market Research Report?

How is the HIV Drugs & Injectables market evolving?

What is driving and restraining the HIV Drugs & Injectables market?

How will each HIV Drugs & Injectables submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each HIV Drugs & Injectables submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading HIV Drugs & Injectables markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the HIV Drugs & Injectables projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of HIV Drugs & Injectables projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the HIV Drugs & Injectables market?

Where is the HIV Drugs & Injectables market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the HIV Drugs & Injectables market today, and over the next 10 years:

Our This 288-page report provides 118 tables, 188 charts exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising HIV Drugs & Injectables prices and recent developments.

Segments Covered in the Report

Drug Class

Combination Therapies (Inclu. InSTI)

Nucleoside and Non-Nucleoside RTIs

Protease Inhibitors

Oral Drugs

Biktarvy

Complera

Delstrigo

Dovato

Genvoya

Juluca

Odefsey

Stribild

Symtuza

Triumeq

Descovy

Truvada

Edurant

Pilfreto

Rukobia

Prezista

Isentress

Tivicay

Long-Acting Injectables

Cabuneva

Sunlenca

Trogarzo

Enfuvirtide

Pre-Exposure Prophylaxis Injectables

Apretude

Lencapavir

Drug Type

Branded

Generics

Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles for some of the leading companies in the HIV Drugs & Injectables Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Bristol Myers Squibb

Frontier Biotechnologies

Gilead Sciences

J&J Innovation Medicine

Merck KGaA

Teva Pharmaceuticals

Theratechnologies

ViiV Healthcare (a GSK Company)

Overall world revenue for HIV Drugs & Injectables Market, 2024 to 2034 in terms of value the market will surpass US$35 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the HIV Drugs & Injectables Market, 2024 to 2034 report help you?

In summary, our 280+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for HIV Drugs & Injectables Market, 2024 to 2034, with forecasts for drug class, oral drug, long acting injectables, PrEP injectables, drug type and distribution channels, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the HIV Drugs & Injectables Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 9 of the major companies involved in the HIV Drugs & Injectables Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the HIV Drugs & Injectables Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to HIV Drugs & Injectables Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 U.S. Targets to End the HIV Epidemic in the Country by 2030
      • 3.3.1.2 Failure for Adherence of Oral HIV Treatment Regimen to drive HIV Injectables Market
      • 3.3.1.3 Long-Acting PrEP will Drive in HIV Prevention Drugs Market
      • 3.3.1.4 Technological Collaborations to Drive the Growth of Long Acting Injectables
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Demand for Newer Drugs Possess a Challenge for Generic Manufacturers
      • 3.3.2.2 Needle Fear and Medical Mistrust
      • 3.3.2.3 Social Stigma
      • 3.3.2.4 Lack of Trained Staff & Infrastructural Facilities
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Demand for Self-Administrating Injectables
      • 3.3.3.2 Broadly Neutralizing Antibodies (bNAbs)
  • 3.4 COVID-19 Impact Analysis
  • 3.5 Supply Chain Analysis
    • 3.5.1 Raw Material Suppliers
    • 3.5.2 Manufacturers
    • 3.5.3 Procurement Agents
    • 3.5.4 Distributors
    • 3.5.5 Service Providers
  • 3.6 Regulatory Framework
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Bargaining Power of Suppliers
    • 3.7.2 Bargaining Power of Buyers
    • 3.7.3 Competitive Rivalry
    • 3.7.4 Threat of Substitutes
    • 3.7.5 Threat of New Entrants
  • 3.8 PEST Analysis
  • 3.9 Emerging Markets and Megatrends
      • 3.9.1.1 Artificial Intelligence in HIV Drug Discovery & Treatment
      • 3.9.1.2 Gene Editing Technologies
      • 3.9.1.3 Nano pharmaceutical drug delivery technologies

4 HIV Drugs & Injectables Market Analysis by Drug Class

  • 4.1 Key Findings
  • 4.2 HIV Drugs & Injectables Segment, By Drug Class: Market Attractiveness Index
  • 4.3 HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
  • 4.4 Combination Therapies (Inclu. InSTI)
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Nucleoside and Non-Nucleoside RTIs
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Protease Inhibitors
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 HIV Therapeutics Oral Drugs Market

  • 5.1 Key Findings
  • 5.2 Indication Segment: Market Attractiveness Index
  • 5.3 HIV Oral Drugs Market Size Estimation and Forecast by Branded Drugs
  • 5.4 Biktarvy
  • 5.5 Complera
  • 5.6 Delstrigo
  • 5.7 Dovato
  • 5.8 Genvoya
  • 5.9 Juluca
  • 5.10 Odefsey
  • 5.11 Stribild
  • 5.12 Symtuza
  • 5.13 Triumeq
  • 5.14 Descovy
  • 5.15 Truvada
  • 5.16 Edurant
  • 5.17 Pifeltro
  • 5.18 Rukobia
  • 5.19 Prezista
  • 5.20 Isentress
  • 5.21 Tivicay

6 HIV Therapeutics Long-Acting Injectable Market, By Drugs

  • 6.1 Key Findings
  • 6.2 Indication Segment: Market Attractiveness Index
  • 6.3 HIV LA & Injectable Drug Market Size Estimation and Forecast by Drugs
  • 6.4 Cabenuva
    • 6.4.1 Cabenuva Market Size, 2024-2034 (US$ Billion)
  • 6.5 Sunlenca
  • 6.6 Trogarzo
  • 6.7 Enfuvirtide (Generic)

7 HIV Pre-Exposure Prophylaxis (PrEP) Injectable Market, By Drugs

  • 7.1 Key Findings
  • 7.2 HIV Pre-Exposure Prophylaxis (PrEP) Market Size Estimation and Forecast by Drugs
  • 7.3 Apretude
    • 7.3.1 Apretude Market Size, 2024-2034 (US$ Billion)
  • 7.4 Lenacapavir (PrEP)
    • 7.4.1 Lenacapavir Market Size, 2024-2034 (US$ Billion)

8 HIV Injectables Market Analysis by Oral Drug Types

  • 8.1 Key Findings
  • 8.2 HIV Oral Drugs Segment, By Types: Market Attractiveness Index
  • 8.3 HIV Oral Drugs Market Size Estimation and Forecast by Drug Types
  • 8.4 Branded
    • 8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.4.2 Market Share by Region, 2024 & 2034 (%)
  • 8.5 Generics
    • 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.5.2 Market Share by Region, 2024 & 2034 (%)

9 Global HIV Drugs & Injectables Market Analysis by Distribution Channel

  • 9.1 Key Findings
  • 9.2 HIV Drugs & Injectables Segment, By Distribution Channel: Market Attractiveness Index
  • 9.3 HIV Drugs & Injectables Size Estimation and Forecast by Distribution Channel
  • 9.4 Hospital Pharmacies
    • 9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.4.2 Market Share by Region, 2024 & 2034 (%)
  • 9.5 Retail Pharmacies
    • 9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.5.2 Market Share by Region, 2024 & 2034 (%)
  • 9.6 Online Pharmacies
    • 9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.6.2 Market Share by Region, 2024 & 2034 (%)

10 HIV Injectables Market Analysis by Pipeline Analysis

  • 10.1 Key Findings

11 HIV Injectables Market Analysis by Regional Share (%) Analysis

  • 11.1 Key Findings
  • 11.2 Regional Market Size Estimation and Forecast

12 North America HIV Drugs & Injectables Market Analysis

  • 12.1 Key Findings
  • 12.2 North America HIV Drugs & Injectables Market Attractiveness Index
  • 12.3 North America HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Country
  • 12.5 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
  • 12.6 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
  • 12.7 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
  • 12.8 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
  • 12.9 U.S. HIV Drugs & Injectables Market Analysis
  • 12.10 Canada HIV Drugs & Injectables Market Analysis

13 Europe Decentralised Clinical Trials Market Analysis

  • 13.1 Key Findings
  • 13.2 Europe HIV Drugs & Injectables Market Attractiveness Index
  • 13.3 Europe HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Country
  • 13.5 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
  • 13.6 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
  • 13.7 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
  • 13.8 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
  • 13.9 UK HIV Drugs & Injectables Market Analysis
  • 13.10 Germany HIV Drugs & Injectables Trials Market Analysis
  • 13.11 France HIV Drugs & Injectables Trials Market Analysis
  • 13.12 Italy HIV Drugs & Injectables Trials Market Analysis
  • 13.13 Spain HIV Drugs & Injectables Trials Market Analysis
  • 13.14 Rest of Europe HIV Drugs & Injectables Trials Market Analysis

14 Asia-Pacific HIV Drugs & Injectables Market Analysis

  • 14.1 Key Findings
  • 14.2 Asia-Pacific HIV Drugs & Injectables Market Attractiveness Index
  • 14.3 Asia-Pacific HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 14.4 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Country
  • 14.5 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
  • 14.6 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
  • 14.7 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
  • 14.8 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
  • 14.9 China HIV Drugs & Injectables Market Analysis
  • 14.10 India HIV Drugs & Injectables Market Analysis
  • 14.11 Japan HIV Drugs & Injectables Market Analysis
  • 14.12 Australia HIV Drugs & Injectables Market Analysis
  • 14.13 South Korea HIV Drugs & Injectables Market Analysis
  • 14.14 Rest of Asia HIV Drugs & Injectables Market Analysis

15 Latin America HIV Drugs & Injectables Market Analysis

  • 15.1 Key Findings
  • 15.2 Latin America HIV Drugs & Injectables Market Attractiveness Index
  • 15.3 Latin America HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 15.4 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Country
  • 15.5 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
  • 15.6 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
  • 15.7 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
  • 15.8 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
  • 15.9 Brazil HIV Drugs & Injectables Market Analysis
  • 15.10 Mexico HIV Drugs & Injectables Market Analysis
  • 15.11 Rest of Latin America HIV Drugs & Injectables Market Analysis

16 MEA HIV Drugs & Injectables Market Analysis

  • 16.1 Key Findings
  • 16.2 MEA HIV Drugs & Injectables Market Attractiveness Index
  • 16.3 MEA HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 16.4 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Country
  • 16.5 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
  • 16.6 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
  • 16.7 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
  • 16.8 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
  • 16.9 South Africa HIV Drugs & Injectables Market Analysis
  • 16.10 GCC HIV Drugs & Injectables Market Analysis
  • 16.11 Rest of MEA HIV Drugs & Injectables Market Analysis

17 Company Profiles

  • 17.1 Competitive Landscape, 2023
  • 17.2 Strategic Outlook
  • 17.3 ViiV Healthcare (a GSK company)
    • 17.3.1 Company Snapshot
    • 17.3.2 Company Overview
    • 17.3.3 Financial Analysis
      • 17.3.3.1 Net Revenue, 2018-2023
      • 17.3.3.2 R&D, 2018-2023
      • 17.3.3.3 Regional Market Shares, 2022
    • 17.3.4 Product Benchmarking
    • 17.3.5 Strategic Outlook
    • 17.3.6 SWOT Analysis
  • 17.4 Gilead Sciences, Inc.
    • 17.4.1 Company Snapshot
    • 17.4.2 Company Overview
    • 17.4.3 Financial Analysis
      • 17.4.3.1 Net Revenue, 2018-2023
      • 17.4.3.2 R&D, 2018-2023
      • 17.4.3.3 Regional Market Shares, 2023
    • 17.4.4 Product Benchmarking
    • 17.4.5 Strategic Outlook
    • 17.4.6 SWOT Analysis
  • 17.5 Merck KGaA
    • 17.5.1 Company Snapshot
    • 17.5.2 Company Overview
    • 17.5.3 Financial Analysis
      • 17.5.3.1 Net Revenue, 2018-2023
      • 17.5.3.2 R&D, 2018-2023
      • 17.5.3.3 Regional Market Shares, 2023
    • 17.5.4 Product Benchmarking
    • 17.5.5 Strategic Outlook
    • 17.5.6 SWOT Analysis
  • 17.6 AbbVie Inc.
    • 17.6.1 Company Snapshot
    • 17.6.2 Company Overview
    • 17.6.3 Financial Analysis
      • 17.6.3.1 Net Revenue, 2018-2023
      • 17.6.3.2 R&D, 2018-2023
      • 17.6.3.3 Regional Market Shares, 2023
    • 17.6.4 Product Benchmarking
    • 17.6.5 Strategic Outlook
  • 17.7 J&J Innovative Medicine ( formerly Janssen Pharma)
    • 17.7.1 Company Snapshot
    • 17.7.2 Company Overview
    • 17.7.3 Financial Analysis
      • 17.7.3.1 Net Revenue, 2018-2023
      • 17.7.3.2 R&D, 2018-2023
      • 17.7.3.3 Regional Market Shares, 2023
    • 17.7.4 Product Benchmarking
    • 17.7.5 Strategic Outlook
  • 17.8 Theratechnologies Inc.
    • 17.8.1 Company Snapshot
    • 17.8.2 Company Overview
    • 17.8.3 Financial Analysis
      • 17.8.3.1 Net Revenue, 2018-2023
      • 17.8.3.2 R&D, 2018-2023
      • 17.8.3.3 Regional Market Shares, 2023
    • 17.8.4 Product Benchmarking
    • 17.8.5 Strategic Outlook
  • 17.9 Teva Pharmaceuticals Inc.
    • 17.9.1 Company Snapshot
    • 17.9.2 Company Overview
    • 17.9.3 Financial Analysis
      • 17.9.3.1 Net Revenue, 2018-2023
      • 17.9.3.2 R&D, 2018-2023
      • 17.9.3.3 Regional Market Shares, 2023
    • 17.9.4 Product Benchmarking
  • 17.10 Frontier Biotechnologies Inc.
    • 17.10.1 Company Snapshot
    • 17.10.2 Company Overview
    • 17.10.3 Product Benchmarking
    • 17.10.4 Strategic Outlook
  • 17.11 Bristol Myers Squibb Inc.
    • 17.11.1 Company Snapshot
    • 17.11.2 Company Overview
    • 17.11.3 Financial Analysis
      • 17.11.3.1 Net Revenue, 2018-2023
      • 17.11.3.2 R&D, 2018-2023
      • 17.11.3.3 Regional Market Shares, 2023
    • 17.11.4 Product Benchmarking
    • 17.11.5 Strategic Outlook

18 Conclusion and Recommendations

  • 18.1 Recommendations for Market Players
  • 18.2 Recommendations for Market Players

List of Tables

  • Table 1 HIV Therapeutics (LA & Injectables) and PrEP Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 HIV Drugs & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 3 Approved Combination Therapies
  • Table 4 HIV Drugs & Injectables Market Forecast by Combination Drugs, By Region 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 5 Approved NRTIs
  • Table 6 Approved NNRTIs
  • Table 7 HIV Drugs Market Forecast by Nucleoside and Non-Nucleoside RTIs Drugs, By Region 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 8 Approved Protease Inhibitors
  • Table 9 HIV Drugs Market Protease Inhibitors Drugs, By Region 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 10 HIV Oral Drugs Market, by Branded Drugs 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 11 Biktravy Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 12 Complera Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 13 Delstrigo Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 14 Dovato Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 15 Genvoya Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 16 Juluca Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 17 Odefsey Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 18 Stribild Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 19 Symtuza Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 20 Triumeq Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 21 Descovy Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 22 Truvada Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 23 Edurant Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 24 Pifeltro Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 25 Rukobia Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 26 Prezista Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 27 Isentress Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 28 Tivicay Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 29 HIV LA & Injectables Market, By Drugs 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 30 Cabuneva Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Table 31 Sunlenca Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 32 Trogarzo Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 33 Enfuvirtide ( Generic) Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 34 Global HIV Pre-Exposure Prophylaxis (PrEP) Injectable Drugs Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 35 Apretude Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 36 Lenacapavir Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Table 37 HIV Drugs Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 38 HIV Drugs Market Forecast by Oral Branded Drugs, By Region 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 39 HIV Drugs Market Forecast by Oral Generic Drugs, By Region 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 40 HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 41 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 42 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 43 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 44 HIV Injectable Drug (ViiV Healthcare) Pipeline Analysis, 2023
  • Table 45 HIV Injectable Drug (Gilead) Pipeline Analysis, 2023
  • Table 46 HIV Injectable Drug (Merck) Pipeline Analysis, 2023
  • Table 47 HIV Injectable Drug (Other Players) Pipeline Analysis, 2023
  • Table 48 HIV Drugs & Injectables Market by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 49 North America HIV Drugs & Injectables Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 50 North America HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 51 North America HIV Drug & Injectables Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 52 North America HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 53 North America HIV Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 54 U.S. HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 55 Canada HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 56 Europe HIV Drugs & Injectables Market Forecast by Country, 2024-2034 (US$ Bn, AGR%, CAGR%)
  • Table 57 Europe HIV Drug Market Forecast HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 58 Europe HIV Drug & Injectables Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 59 Europe HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 60 Europe HIV Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Bn, AGR%, CAGR%)
  • Table 61 UK HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 62 Germany HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 63 France HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 64 Italy HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 65 Spain HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 66 Rest of Europe HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 67 Asia HIV Drugs & Injectables Market Forecast by Country, 2023-2033 (US$ Mn, AGR%, CAGR%)
  • Table 68 Asia HIV Drugs & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Mn, AGR%, CAGR%)
  • Table 69 Asia HIV Drugs Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 70 Asia HIV Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 71 Asia-Pacific HIV Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Bn, AGR%, CAGR%)
  • Table 72 China HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 73 India HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 74 Japan HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 75 Australia HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 76 South Korea. HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 77 Rest of Asia HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 78 Latin America HIV Drugs & Injectables Market Forecast by Country, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 79 Latin America HIV Drugs & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Bn, AGR%, CAGR%)
  • Table 80 Latin America HIV Drugs Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 81 Latin America HIV Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 82 Latin America HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 83 Brazil HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 84 Mexico HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 85 Rest of Latin America HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 86 Middle East & Africa HIV Drugs & Injectables Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 87 Middle East & Africa HIV Drugs & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Bn, AGR%, CAGR%)
  • Table 88 Middle East & Africa HIV Drugs Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 89 Middle East & Africa HIV Drugs & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 90 Middle East & Africa HIV Drugs & Injectables Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 91 South Africa HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 92 GCC HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 93 Rest of Middle East & Africa HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 94 Strategic Outlook
  • Table 95 ViiV Healthcare: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 ViiV Healthcare: Product Benchmarking
  • Table 97 ViiV Healthcare : Strategic Outlook
  • Table 98 Gilead Sciences, Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Gilead Sciences Inc.: Product Benchmarking
  • Table 100 Gilead Sciences, Inc. : Strategic Outlook
  • Table 101 Merck KGaA, Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Merck KGaA Inc.: Product Benchmarking
  • Table 103 Merck KGaA, Inc. : Strategic Outlook
  • Table 104 AbbVie Inc., Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 AbbVie Inc. : Product Benchmarking
  • Table 106 AbbVie Inc., Inc. : Strategic Outlook
  • Table 107 Johnson & Johnson Innovative Medicine, Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Johnson & Johnson Innovative Medicine : Product Benchmarking
  • Table 109 Johnson & Johnson Innovative Medicine, Inc. : Strategic Outlook
  • Table 110 Theratechnologies Inc., Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Theratechnologies Inc. : Product Benchmarking
  • Table 112 Theratechnologies Inc. : Strategic Outlook
  • Table 113 Teva Pharmaceuticals Inc., Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 Teva Pharmaceuticals Inc. : Product Benchmarking
  • Table 115 Frontier Biotechnologies Inc., Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Frontier Biotechnologies Inc. : Product Benchmarking
  • Table 117 Frontier Biotechnologies Inc. : Strategic Outlook
  • Table 118 Bristol Myers Squibb Inc., Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Bristol Myers Squibb Inc. : Product Benchmarking

List of Figures

  • Figure 1 HIV Drugs & Injectables Market Segmentation
  • Figure 2 HIV Drugs & Injectables Market Attractiveness Index by Region
  • Figure 3 HIV Drugs & Injectables Market Attractiveness Index by Drug Class
  • Figure 4 HIV Drugs & Injectables Market Attractiveness Index by Oral Drugs
  • Figure 5 HIV Drugs & Injectables Market Attractiveness Index by LA Injectables
  • Figure 6 HIV Drugs & Injectables Market Attractiveness Index by Oral Drug Types
  • Figure 7 HIV Drugs & Injectables Market Attractiveness Index by Distribution Channels
  • Figure 8 HIV Injectables Trials Market: Market Dynamics
  • Figure 9 HIV Drugs & Injectables Market: Impact Analysis
  • Figure 10 HIV Drugs & Injectables Market: Supply Chain Analysis
  • Figure 11 HIV Therapeutics Drugs & Injectables Market: Porter's Five Forces Analysis
  • Figure 12 HIV Long-Acting Injectable Drugs Market: PEST Analysis
  • Figure 13 HIV Drugs & Injectables Segment By Drug Class : Market Attractiveness Index
  • Figure 14 HIV Drugs & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 15 HIV Drugs Market Forecast by Oral Drug Types, 2024, 2029, 2034 (%)
  • Figure 16 HIV Combination Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 17 HIV Combination Drugs Market Forecast by Region, 2024-2034 (%)
  • Figure 18 HIV Nucleoside & Non-Nucleoside RTIs Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 19 HIV Nucleoside & Non-Nucleoside RTIs Drugs Market Forecast by Region, 2024-2034 (%)
  • Figure 20 HIV Protease Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 21 HIV Protease Drugs Market Forecast by Region, 2024-2034 (%)
  • Figure 22 HIV Therapeutics Oral Drugs: Market Attractiveness Index
  • Figure 23 HIV Oral Drugs Market Forecast by Branded Drugs, 2024-2034 (US$ Billion, AGR %)
  • Figure 24 HIV Oral Drugs Market Forecast by Branded Drugs, 2024, 2029, 2034 (%)
  • Figure 25 Biktravy Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 26 Complera Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 27 Delstrigo Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 28 Dovato Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 29 Genvoya Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 30 Juluca Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 31 Odefsey Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 32 Stribild Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 33 Symtuza Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 34 Triumeq Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 35 Descovy Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 36 Truvada Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 37 Edurant Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 38 Pifeltro Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 39 Rukobia Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 40 Prezista Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 41 Isentress Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 42 Tivicay Market, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 43 HIV Therapeutics Injectable: Market Attractiveness Index
  • Figure 44 HIV LA & Injectables Market, By Drugs 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 45 HIV LA & Injectables Market by Drugs, 2023, 2028, 2033 (%)
  • Figure 46 Cabenuva Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 47 Sunlenca Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 48 Trogarzo Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 49 Enfuvirtide (Generic) Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 50 Global HIV Pre-Exposure Prophylaxis (PrEP) Injectable Drugs Market,2024-2034 (US$ Bn, AGR (%)
  • Figure 51 Apretude Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 52 Lenacapavir PrEP Market, 2024-2034 (US$ Bn, AGR (%), CAGR (%))
  • Figure 53 HIV Oral Drugs Segment By Type : Market Attractiveness Index
  • Figure 54 HIV Drugs Market Forecast by Oral Drug Types, 2024-2034 (US$ Billion, AGR %)
  • Figure 55 HIV Drugs Market Forecast by Oral Drug Types, 2024, 2029, 2034 (%)
  • Figure 56 HIV Oral Branded Drugs Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 57 HIV Oral Branded Drugs Segment Market Forecast by Region, 2024-2034 (%)
  • Figure 58 HIV Oral Generics Drugs Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 59 HIV Oral Generics Drugs Segment Market Forecast by Region, 2024-2034 (%)
  • Figure 60 HIV Drugs & Injectables Segment By Distribution Channel : Market Attractiveness Index
  • Figure 61 HIV Drugs & Injectables Market Forecast by Distribution, 2024-2034 (US$ Billion, AGR %)
  • Figure 62 HIV Drugs Market Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 63 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%)
  • Figure 64 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (%)
  • Figure 65 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%)
  • Figure 66 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (%)
  • Figure 67 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%)
  • Figure 68 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (%)
  • Figure 69 HIV Drugs & Injectables Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 70 HIV Drugs & Injectables Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 71 HIV Injectables Trials Market by Region, 2023 (%)
  • Figure 72 HIV Drugs & Injectables Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 73 North America HIV Drugs & Injectables Market Attractiveness Index
  • Figure 74 North America HIV Drugs & Injectables Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 75 North America HIV Drugs & Injectables Market Forecast by Country Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 76 North America HIV Drugs & Injectables Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 77 North America HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 78 North America HIV Drug & Injectables Market Forecast By Drug Type, 2024 & 2034 (%)
  • Figure 79 North America HIV Drug & Injectables Market Forecast By Oral Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 North America HIV Drug & Injectables Market Forecast By Oral Drug Type, 2024 & 2034 (%)
  • Figure 81 North America HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 North America HIV Drug & Injectables Market Forecast, by Drug Class 2024 & 2034 (%)
  • Figure 83 North America HIV Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 84 North America HIV Drugs Market Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 85 U.S. HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 86 Canada HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 87 Europe HIV Drugs & Injectables Market Attractiveness Index
  • Figure 88 Europe HIV Drugs & Injectables Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 89 Europe HIV Drugs & Injectables Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 90 Europe HIV Drugs & Injectables Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 91 Europe HIV Drugs & Injectables Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 92 Europe HIV Drug Market Forecast HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 93 Europe HIV Drug Market Forecast HIV Drug & Injectables Market Forecast By Drug Type, 2024 & 2034 (%)
  • Figure 94 Europe HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024-2034 (US$ Billion, AGR %)
  • Figure 95 Europe HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024 & 2034 (%)
  • Figure 96 Europe HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 97 Europe HIV Drug & Injectables Market Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 98 Europe HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 99 Europe HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 100 UK HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 101 Germany HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 France HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 103 Italy HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 104 Spain HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 105 Rest of Europe HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 Asia-Pacific HIV Drugs & Injectables Market Attractiveness Index
  • Figure 107 Asia-Pacific HIV Drugs & Injectables Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 108 Asia-Pacific HIV Drugs & Injectables Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 109 Asia-Pacific HIV Drugs & Injectables Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 110 Asia-Pacific HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 111 Asia-Pacific HIV Drug & Injectables Market Forecast By Drug Type, 2024 & 2034 (%)
  • Figure 112 Asia-Pacific HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Asia-Pacific HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024 & 2034 (%)
  • Figure 114 Asia-Pacific HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 115 Asia-Pacific HIV Drug & Injectables Market Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 116 Asia-Pacific HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 117 Asia-Pacific HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 118 China HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 119 India HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 120 Japan HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 121 Australia HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 122 South Korea HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 123 Rest of Asia HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 124 Latin America HIV Drugs & Injectables Market Attractiveness Index
  • Figure 125 Latin America HIV Drugs & Injectables Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 126 Latin America HIV Drugs & Injectables Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 Latin America HIV Drugs & Injectables Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 128 Latin America HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 129 Latin America HIV Drug & Injectables Market Forecast By Drug Type, 2024 & 2034 (%)
  • Figure 130 Latin America HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024-2034 (US$ Billion, AGR %)
  • Figure 131 Latin America HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024 & 2034 (%)
  • Figure 132 Latin America HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 133 Latin America HIV Drug & Injectables Market Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 134 Latin America HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 135 Latin America HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 136 Brazil HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 137 Mexico HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 138 Rest of Latin America HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 139 MEA HIV Drugs & Injectables Market Attractiveness Index
  • Figure 140 MEA HIV Drugs & Injectables Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 141 MEA HIV Drugs & Injectables Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 142 MEA HIV Drugs & Injectables Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 143 Middle East Africa HIV Drug & Injectables Market Forecast By Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 144 Middle East Africa HIV Drug & Injectables Market Forecast By Drug Type, 2024 & 2034 (%)
  • Figure 145 Middle East Africa HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024-2034 (US$ Billion, AGR %)
  • Figure 146 Middle East & Africa HIV Drugs & Injectables Market Forecast By Oral Drug Types, 2024 & 2034 (%)
  • Figure 147 Middle East & Africa HIV Drug & Injectables Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 148 MEA HIV Drug & Injectables Market Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 149 Middle East & Africa HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 150 Middle East & Africa HIV Drugs & Injectables Market Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 151 South Africa HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 152 GCC HIV Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 153 Rest of Middle East & Africa Drugs & Injectables Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Figure 154 HIV Drugs Market: Company Share Analysis, 2023
  • Figure 155 HIV LA Injectable Drugs Market: Company Share Analysis, 2023
  • Figure 156 ViiV Healthcare : Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 157 ViiV Healthcare: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 158 ViiV Healthcare: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 159 ViiV Healthcare: Regional Market Shares, 2023
  • Figure 160 ViiV Healthcare: SWOT Analysis
  • Figure 161 Gilead Sciences, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 162 Gilead Sciences, Inc : HIV Division: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 163 Gilead Sciences,Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 164 Gilead Sciences,Inc: Regional Market Shares, 2023
  • Figure 165 Gilead Sciences: SWOT Analysis
  • Figure 166 Merck KGaA, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 167 Merck KGaA, Inc : HIV Division: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 168 Merck KGaA,Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 169 Merck KGaA,Inc: Regional Market Shares, 2023
  • Figure 170 Merck KGaA: SWOT Analysis
  • Figure 171 AbbVie Inc., Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 172 AbbVie Inc., : HIV Division: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 173 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 174 AbbVie Inc.: Regional Market Shares, 2023
  • Figure 175 Johnson & Johnson, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 176 Johnson & Johnson Innovative Medicine.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 177 Johnson & Johnson Innovative Medicine, : HIV Division: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 178 Johnson & Johnson: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 179 Johnson & Johnson Innovative Medicine: Regional Market Shares, 2023
  • Figure 180 Theratechnologies Inc., Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 181 Theratechnologies Inc., : HIV Division: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 182 Theratechnologies Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 183 Theratechnologies Inc.: Regional Market Shares, 2023
  • Figure 184 Teva Pharmaceuticals Inc., Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 185 Teva Pharmaceuticals Inc., Inc.: HIV Generic Drugs Net Revenue, 2022 (US$ Million, AGR%)
  • Figure 186 Teva Pharmaceuticals Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 187 Teva Pharmaceuticals Inc.: Regional Market Shares, 2023
  • Figure 188 Bristol Myers Squibb.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 189 Bristol Myers Squibb.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 190 Bristol Myers Squibb.: Regional Market Shares, 2023